patent.fyi
Applications  /  US 2026/0356804
United States Patent Application Publication

US 2026/0356804 A1

Published
Nov 12, 2026
Filed
Sep 8, 2023
Earliest date on the face
Sep 9, 2022
Classification
C07D 213/82
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Cyano substituted phenyl ring

What ifWhat if A uses a 3-cyanophenyl group in place of the heteroaryl ring?
Claim language“substituted or unsubstituted heteroaryl ring”

The phenyl ring provides a planar aromatic surface. The nitrile nitrogen provides a hydrogen-bond acceptor outside the ring, two ring bonds from the scaffold attachment site.

1.4Saturated bicyclic group at B

What ifWhat if B uses a bicyclo[2.2.2]octan-1-yl group?
Claim language“substituted or unsubstituted aryl or heteroaryl”

The scaffold attaches to a bridgehead carbon of the saturated bicyclic group. Three ethylene bridges hold the group in a rigid shape and provide a nonpolar contact surface.

1.7Cyano substitution on ring C

What ifWhat if C is a phenyl ring with a cyano group para to its scaffold attachment?
Claim language“halo, C1-C8 alkyl, haloalkyl, alkoxy”

The nitrile projects from the para carbon along the long axis of the substituted phenyl group. Its terminal nitrogen provides a hydrogen-bond acceptor, and the carbon–nitrogen triple bond contributes a local dipole.

1.8Cyclopropyl group at R1

What ifWhat if R1 is cyclopropyl?
Claim language“H and C1-C4 alkyl”

The scaffold bonds directly to one carbon of the three-membered ring. The two remaining ring carbons form a compact hydrophobic group with a fixed internal geometry.

1.9Primary sulfonamide at R2

What ifWhat if R2 uses a primary sulfonamide attached through sulfur?
Claim language“C(═O)NH2, and —C(═O)NR′R″”

The group attaches through a scaffold–sulfur bond and terminates in —SO₂NH₂. Its sulfonyl oxygens provide hydrogen-bond acceptor sites, and its NH₂ group provides a donor site.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Sodium channel blockade in sensory assays

A cultured sensory neuron assay uses a compound of formula (I) as a reference for sodium channel blockade during electrical stimulation. Separate wells receive vehicle, the reference compound, or a test material. A microelectrode array records evoked spike counts before and after exposure, and the reference wells show how the assay responds to a sodium channel blocker.

Component substitution

Five membered thiazole at position A

A thiazol-2-yl group replaces a pyridyl group at position A and attaches to the scaffold through carbon 2 of the thiazole ring. The B and C rings and the R1 and R2 groups are identical in the two compounds. Whole-cell voltage clamp measures Nav1.8 current over the same concentration series for both compounds.

Cyclic carboxamide at position R2

A pyrrolidin-1-ylcarbonyl group replaces the primary carboxamide at R2 and retains the bond from the scaffold to the carbonyl carbon. The amide nitrogen forms part of the five-membered pyrrolidine ring, and positions A, B, C, and R1 match those of the primary carboxamide. Liquid chromatography measures the dissolved concentration of each compound in assay buffer, and voltage-clamp recordings compare Nav1.8 current at matched dissolved concentrations.

Parameter or scale variation

Pulse frequency series for channel blockade

A whole-cell voltage clamp assay delivers trains of 20 depolarizing pulses at 1, 5, and 10 Hz to cells expressing Nav1.8. Each pulse steps from −100 mV to +10 mV for 20 ms, and the cell rests at −100 mV for 60 seconds between trains. At each frequency, the ratio of the twentieth peak current to the first is compared between compound and vehicle recordings.

Combination with existing systems

Channel blockade in a perfused neuron chip

A two-compartment microfluidic chip holds sensory neuron cell bodies in one chamber and guides their axons through microgrooves into a separately perfused chamber. The axon chamber receives a solution containing a compound of formula (I), while the cell body chamber receives vehicle. An extracellular electrode stimulates the axons upstream of the exposed segment, and an electrode in the cell body chamber records the fraction of pulses that produce a propagated spike.

Automated or data-driven variant

Automated fitting of channel blockade curves

A liquid handler prepares an eight-point, threefold dilution series of a compound of formula (I) and dispenses it into an automated patch-clamp plate containing cells that express Nav1.8. The instrument records peak inward current before and after compound exposure, and software normalizes each response to its baseline and the time-matched vehicle response. The software fits a four-parameter logistic curve and reports the concentration at the midpoint when the measured responses span that midpoint.

Specific version of a part

Trifluoromethyl substitution on pyridine

A is a pyridin-2-yl group bearing trifluoromethyl at ring position 5. The substituent attaches through its carbon and contains three fluorines on that carbon.

Oxygen in a four-membered ring

An oxetan-3-yl substituent attaches to A through the carbon opposite the ring oxygen. The saturated four-membered ring contains three carbons and one ether oxygen.

Trideuteromethyl substitution on B

B is a phenyl group bearing —CD₃ at the carbon para to the scaffold attachment. All three hydrogen positions on the methyl carbon are occupied by deuterium.

Pyridine ring at C

C is an unsubstituted pyridin-3-yl group linked to the scaffold through pyridine carbon 3. The aromatic ring nitrogen occupies position 1 and provides a hydrogen-bond acceptor.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0249170 A1
Published
Sep 4, 2014
Filed
Sep 18, 2012
Class
C07D 498/10
Document BUS 2015/0322052 A1
Published
Nov 12, 2015
Filed
Jul 2, 2015
Class
C07D 405/12
Claim 1
Document A
Document B
1.1A is a substituted or unsubstituted heteroaryl ring comprising at least one heteroatom selected from a group consisting of O, S, or N
A compound of formula A or its prodrugs, tautomeric forms, stereoisomers, optical isomers, pharmaceutically acceptable salts, solvates or polymorphs thereof, wherein is 5-membered heterocyclic ring substituted with alkyl chain at 2 or 3, or 8-10 membered bicyclic group wherein a six membered heterocyclic ring is fused with 5-membered heterocyclic ring; represents a 5-10 membered monocyclic or bicyclic heteroaryl ring, 5-10 membered monocyclic or bicyclic heterocycloalkyl grou
A · US 2014/0249170 A1 · claim 1
W, Y and Z are independently selected from nitrogen atom and carbon atom, which are independently optionally substituted with R1; at least one of W, Y and Z is nitrogen and W, Y and Z are not carbon at the same time;
B · US 2015/0322052 A1 · claim 14
1.2wherein the one or more substitutions on A are selected from H, —OH, halo, C1-C8-alkyl, C1-C8 fully or partially fluorinated fluoroalkyl, C2-C8 branched alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, cycloalkoxy, haloalkoxy, nitro, cyano, —C(R′)(R″)-cycloalkyl, C(R′)(R″)-aryl, —NR′R″, substituted or unsubstituted 3-8 membered cycloalkyl, 3-8 membered cycloalkenyl, or 3-6 membered heterocycloalkyl
R3, R4, R5 and R6 are independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogen, (4) C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from R7, (5) C3-6 cycloalkyl, which is unsubstituted or substituted with one or more substituents independently selected from R7, (6) —O—C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from R7, (7) —O—C
B · US 2015/0322052 A1 · claim 14
1.3wherein the 3-6 membered heterocycloalkyl comprises at least one heteroatom independently selected from O, S, and N
R9 and R10 are independently hydrogen or C1-6 alkyl, which is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, and —O—C1-6 alkyl; or R9 form a 4 to 7 membered ring with R10 which may contain nitrogen atom, oxygen atom, sulfur atom or double bond, wherein the 4 to 7 membered ring is optionally substituted with 1 to 6 substituents independently selected from the group consisting of: (1) hydrogen, (2) hydroxyl, (3) halogen
B · US 2015/0322052 A1 · ¶ 51
1.4B is substituted or unsubstituted aryl or heteroaryl
L is selected from H, alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl;
A · US 2014/0249170 A1 · ¶ 13
Ar is aryl which is optionally substituted with 1 to 5 substituents independently selected from the group consisting of: (1) halogen, (2) hydroxyl, (3) —On—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (4) —NR9R10, and (5) —CN; wherein n is 0 or 1; when n is 0, a chemical bond is present in the place of On; or a pharmaceutically acceptable salt thereof.
B · US 2015/0322052 A1 · claim 14
1.5wherein the substitutions are selected from the group consisting of substituted or unsubstituted C1-C8 alkyl, deuterated C1-C4 alkyl wherein the alkyl chain may be fully or partially deuterated, halo-C1-C4 alkyl where the alkyl chain is fully or partially halogenated, C3-C10 cycloalkyl, halogen, cyano, nitro, C1-C8 alkoxyl, haloalkoxyl wherein the haloalkyoxyl chain may be fully or partially halogenated, or arylalkoxyl
R is selected from small alky group or halogen substitution;
A · US 2014/0249170 A1 · claim 1
1.6C is substituted or unsubstituted aryl or heteroaryl
1.7wherein the one or more substitutions are independently selected from a group consisting of halo, C1-C8 alkyl, haloalkyl, alkoxy
1.8R1 is selected from a group consisting of H and C1-C4 alkyl
wherein E3 is selected from the group consisting of —CH2—, NH, NMe and O; and R1 and R2 are independently selected from the group consisting of methyl, ethyl, n-propyl and alkyl chain (C4-C9).
A · US 2014/0249170 A1 · ¶
(1) hydrogen, (2) —On—C1-6 alkyl, where the alkyl is unsubstituted or substituted with one or more substituents independently selected from R7, (3) —On—C1-6 cycloalkyl, where the cycloalkyl is unsubstituted or substituted with one or more substituents independently selected from R7, and (4) —On-heterocyclic group, where the heterocyclic group is unsubstituted or substituted with one or more substituents independently selected from R7; wherein n is 0 or 1, when n is 0, a chemi
B · US 2015/0322052 A1 · claim 14
1.9R2 is selected from a group consisting of: Formula (II): C(═O)NH2, and —C(═O)NR′R″
1.10wherein, m and n are independently 0 or 1
1.11X1 is O and X2 is either NH or NR′
1.12or X1 and X2 are both O, NH, or NR′ or X1 is O and X2 is NR3 wherein R3 is selected from a group consisting of: CD3, C1-C4 alkyl or cycloalkyl, haloalkyl, halocycloalkyl, aryl, heteroaryl, and heterocyclyl, (C1-C6)alkyl-OH, (C1-C6)alkyl-NHR′, (C1-C6)alkyl-NR′R″, (C1-C6)alkyl-O—(C1-C6)alkyl, (C1-C6)alkyl-N—(C1-C6)alkyl R4 is selected from a group consisting of: —NH2, —NR′R″, C1-C4 alkyl, C3-C8-cycloalkyl, haloalkyl, halocycloalkyl, aryl, heteroaryl, and heterocyclyl.
wherein E3 and E4 are independently selected from the group consisting of —CH2— and NH and N with the proviso that both E3 and E4 are NH or one of E3, E4 is NH or one of E3, E4 is NH while one of E3, E4 is N—X-L and R3 is selected from a group consisting of small alkyl group comprising methyl, ethyl or n-propyl and 3-6 membered cycloalkyl ring.
A · US 2014/0249170 A1 · ¶

An empty cell means only that no passage was reproduced there.

Statements in these documents
Given the high level of drug resistance and the large unmet clinical need, novel agents to treat S. aureus infections are urgently needed.
A · US 2014/0249170 A1 · ¶ 6
This invention is related to novel compounds which specifically inhibit bacterial FabI for the treatment of Staphylococcal infections.
A · US 2014/0249170 A1 · ¶ 2
The present invention relates to aryl substituted carboxamide derivatives which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved.
B · US 2015/0322052 A1 · ¶ 1
The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
B · US 2015/0322052 A1 · ¶ 1
Cite aspatent.fyi, US 2026/0356804 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356804/, SHA-256 838df3d7670e2ad2ed22518c7e7619d4e900b0c4a7da01e3849c08d59d0a465d
First published
Permanent addresshttps://patent.fyi/US20260356804/
Content fingerprint (SHA-256)838df3d7670e2ad2ed22518c7e7619d4e900b0c4a7da01e3849c08d59d0a465d
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi